.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The SIROCCO phase 3 trial evaluated benralizumab, an anti-IL-5 receptor monoclonal antibody, in patients with severe uncontrolled asthma despite high-dose inhaled corticosteroid plus LABA therapy and evidence of eosinophilia. More than 1,200 patients were randomized to benralizumab or placebo, with treatment given every four weeks or, after an initial dosing phase, every eight weeks. In patients with elevated blood eosinophils, benralizumab significantly reduced annualized asthma exacerbation rates and improved prebronchodilator FEV1 compared with placebo. The findings helped establish eosinophilic asthma as a clinically actionable phenotype for biologic therapy. For HCPs, the study reinforces a practical sequence: confirm the diagnosis, optimize inhaled treatment and adherence, identify type-2 biomarkers, and then select a biologic for appropriately severe disease. This fits directly with the NAPCON sessions on asthma phenotyping, early biologic therapy and the distinction between eosinophilic and non-eosinophilic disease. The paper is particularly useful for explaining why blood eosinophils can help guide treatment selection, while also emphasizing that biologic choice should be made in the context of the whole clinical picture rather than a single biomarker alone.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The SIROCCO phase 3 trial evaluated benralizumab, an anti-IL-5 receptor monoclonal antibody, in patients with severe uncontrolled asthma despite high-dose inhaled corticosteroid plus LABA therapy and evidence of eosinophilia. More than 1,200 patients were randomized to benralizumab or placebo, with treatment given every four weeks or, after an initial dosing phase, every eight weeks. In patients with elevated blood eosinophils, benralizumab significantly reduced annualized asthma exacerbation rates and improved prebronchodilator FEV1 compared with placebo. The findings helped establish eosinophilic asthma as a clinically actionable phenotype for biologic therapy. For HCPs, the study reinforces a practical sequence: confirm the diagnosis, optimize inhaled treatment and adherence, identify type-2 biomarkers, and then select a biologic for appropriately severe disease. This fits directly with the NAPCON sessions on asthma phenotyping, early biologic therapy and the distinction between eosinophilic and non-eosinophilic disease. The paper is particularly useful for explaining why blood eosinophils can help guide treatment selection, while also emphasizing that biologic choice should be made in the context of the whole clinical picture rather than a single biomarker alone.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
5 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
